LENZ THERAPEUTICS INC (LENZ) Stock Price & Overview
NASDAQ:LENZ • US52635N1037
Current stock price
The current stock price of LENZ is 9.67 USD. Today LENZ is up by 3.42%. In the past month the price decreased by -19.82%. In the past year, price decreased by -54.34%.
LENZ Key Statistics
- Market Cap
- 302.574M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.79
- Dividend Yield
- N/A
LENZ Stock Performance
LENZ Stock Chart
LENZ Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LENZ. When comparing the yearly performance of all stocks, LENZ is a bad performer in the overall market: 94.4% of all stocks are doing better.
LENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LENZ. While LENZ has a great health rating, there are worries on its profitability.
LENZ Earnings
On March 24, 2026 LENZ reported an EPS of -1.16 and a revenue of 1.59M. The company missed EPS expectations (-17.11% surprise) and missed revenue expectations (-17.46% surprise).
LENZ Forecast & Estimates
13 analysts have analysed LENZ and the average price target is 49.16 USD. This implies a price increase of 408.42% is expected in the next year compared to the current price of 9.67.
For the next year, analysts expect an EPS growth of -9.4% and a revenue growth 48.14% for LENZ
LENZ Groups
Sector & Classification
LENZ Financial Highlights
Over the last trailing twelve months LENZ reported a non-GAAP Earnings per Share(EPS) of -2.79. The EPS increased by 41.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.85% | ||
| ROE | -28.88% | ||
| Debt/Equity | 0 |
LENZ Ownership
LENZ Latest News, Press Relases and Analysis
LENZ Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LENZ
Company Profile
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Company Info
IPO: 2021-06-25
LENZ THERAPEUTICS INC
201 Lomas Santa Fe Drive, Suite 300
Solana Beach CALIFORNIA US
Employees: 42
Phone: 18589257000
LENZ THERAPEUTICS INC / LENZ FAQ
Can you describe the business of LENZ THERAPEUTICS INC?
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 42 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Can you provide the latest stock price for LENZ THERAPEUTICS INC?
The current stock price of LENZ is 9.67 USD. The price increased by 3.42% in the last trading session.
Does LENZ THERAPEUTICS INC pay dividends?
LENZ does not pay a dividend.
What is the ChartMill technical and fundamental rating of LENZ stock?
LENZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does LENZ THERAPEUTICS INC have?
LENZ THERAPEUTICS INC (LENZ) currently has 42 employees.
Can you provide the upcoming earnings date for LENZ THERAPEUTICS INC?
LENZ THERAPEUTICS INC (LENZ) will report earnings on 2026-05-04.
Can you provide the ownership details for LENZ stock?
You can find the ownership structure of LENZ THERAPEUTICS INC (LENZ) on the Ownership tab.